Percutaneous radiofrequency ablation versus surgical radiofrequency ablation for malignant liver tumours: the long‐term results  by Wong, John et al.
ORIGINAL ARTICLE
Percutaneous radiofrequency ablation versus surgical
radiofrequency ablation for malignant liver tumours:
the long-term results
John Wong1, Kit-Fai Lee1, Simon Chun-Ho Yu2, Paul Sing-Fun Lee2, Yue-Sun Cheung1, Ching-Ning Chong1,
Philip Ching-Tak Ip1 & Paul Bo-San Lai1
1Division of Hepato-biliary and Pancreatic Surgery, Department of Surgery and 2Department of Imaging and Interventional Radiology, The Chinese University
of Hong Kong, Prince of Wales Hospital, Hong Kong SAR, China
Abstract
Background: Radiofrequency ablation (RFA) has been used to treat hepatocellular carcinoma (HCC) and
liver metastases for more than 10 years with promising early outcomes. Preliminary results comparing
percutaneous and surgical approaches have shown no difference in short-term outcomes. In this study,
the longer-term outcomes were presented.
Methods: Patients with liver malignancies treated by RFA were prospectively studied from 2003 to 2011.
Post-ablation assessment by computed tomography (CT) scan and serum biochemistry was performed
at regular intervals. Recurrence rates and long-term survival were analysed.
Results: A total of 233 patients with liver malignancies (75.5% HCC and 24.5% liver metastases) were
analysed. Three RFA approaches were used (percutaneous 58.4%, laparoscopic 9.4% and open 32.2%).
The median follow-up time was 29 months. Complete ablation was achieved in 83.7%, with no difference
between the two approaches. More wound and chest complications were observed in the surgical group.
Intra-hepatic recurrences were observed in 69.5%; extra-hepatic recurrences were detected in 22.3%,
with no difference between the two groups. There was no statistical difference between the two
approaches in overall 1-, 3- and 5-year survival.
Conclusion: An extended period of follow-up in patients with liver malignancies showed that RFA is an
effective treatment. No difference was demonstrated between the percutaneous and surgical approach,
in terms of recurrence and survival.
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Introduction
Hepatocellular carcinoma (HCC) is one of the six most common
cancers worldwide and is the third most frequent cause of cancer
death.1 It has constituted an important problem for healthcare
systems owing to its high morbidity, mortality and progressive
incidence.2 HCC is known to be an aggressive tumour that
usually develops in a cirrhotic liver with limited functional
reserve and, without proper treatment, the prognosis is usually
poor. In the future decades, it is estimated that its incidence will
continue to rise in the western world, particularly in the United
States, Canada and southern Europe. It seems that hepatitis
C-related HCC is the major contributing factor to such an
increasing trend.3–5
Although surveillance programmes for high-risk patients with
cirrhosis and chronic hepatitis have been undertaken for decades
in Taiwan and Asia, only 10–30% of HCC patients were presented
as early stage at diagnosis.6 This may be because of the fact that
many people may still not recognize the risks of this disease and
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therefore do not receive surveillance. As a result, the incidence of
HCC is particularly high among Asians.
A liver resection remains the ‘gold standard’ for curative treat-
ment, but is only suitable for a minority of patients.7 Similarly, up
to 80% of patients with colorectal liver metastasis may not be
candidates for a hepatectomy.8 In the past 10 years, there has been
growing interest in radiofrequency ablation (RFA) for treating
liver tumours. This has been widely accepted as an effective
modality for treating unresectable HCC and liver secondary. Its
safety and therapeutic efficacy have been confirmed in a system-
atic review and meta-analysis.9,10 Consensus meetings of major
scientific societies have presented guidelines for its use. In both of
the evidence-based practice guidelines proposed by the European
Association of Study of Liver (EASL) and the American Associa-
tion of Study of the Liver Disease (AASLD), RFA is recommended
as a non-surgical technique for the treatment of early stage
HCC.11,12
The preliminary results (up to year 2006) comparing percuta-
neous and surgical approaches, which showed no difference in
short-term outcome, have been reported.13 The objective of this
study was to examine the longer-term results with regard to local
recurrence and overall survival rates. The major differences in the
outcome of patients treated by the different approaches were also
evaluated.
Materials and methods
Pre-procedural assessment and patient selection
Before RFAs, all patients were assessed clinically by the same team
of HPB surgeons. Biochemistry investigations, including liver
function tests, coagulation profile, hepatitis B and hepatitis C
serology, alpha-fetoprotein (AFP) and carcinoembryonic antigen
(CEA) were performed. Radiologically, all patients had a chest
X-ray, trans-abdominal ultrasonography, followed by a three-
phase enhanced computed tomography (CT) scan. In situations
where the diagnosis was uncertain, a liver biopsy was performed
prior to ablation. All benign conditions were excluded. If the liver
lesion was suitable for curative-intent resection, a hepatectomy
would be the first treatment option offered. The Indocyanine
Green Clearance test was used to assess the hepatic reserve. RFA
would be offered to patients not suitable for a curative-intent
resection. If a surgical RF approach was contemplated, the patient
would be seen by an anaesthetist for standard cardiopulmonary
assessment.
In the present study, all RFA procedures were performed either
percutaneously or surgically (laparoscopic or open approach).
Parameters including tumour size, number and location, previous
abdominal operations, general anaesthetic risk as well as the
necessity for concomitant operative procedures were all taken into
account when planning for the approach used.
The patient selection criteria for RFA followed the published
recommendations.14 The maximum dimension of the tumours
was not greater than 5 cm on computed tomography (CT) scan
measurement. There must be no evidence of extrahepatic disease
upon planning for RFA. Each patient could only be registered as
one entry into the database at the time they first received RFA
treatment.
Selection of RFA approach
The percutaneous approach remained the first choice of treatment
if technically feasible (as this would be least invasive for the
patient), followed by the laparoscopic and open approach. Subcap-
sular tumours and lesions located too close to major vessels or bile
ducts were considered unsafe for the percutaneous approach, and a
surgical route would have to be considered instead. A laparoscopic
approach would be chosen for tumours located close to the gall-
bladder, of which a laparoscopic cholecystectomy would be per-
formed at the same time. For lesions located at the posterior aspect
of the left lobe, the stomach would be insulated from the RFA site by
a piece of gauze soaked with cold saline. An open approach would
be indicated for patients with multiple previous abdominal surger-
ies, or tumours in close proximity to surrounding organs that
required meticulous adhesiolysis. An open approach would also be
necessary if the tumour was situated at the right posterior sector,
where a full mobilization of the right lobe was needed. The degree
of freedom for the safe introduction of the RFA needle into the
target was also taken into consideration.
RFA technique
All percutaneous RFAs were performed by the same team of spe-
cialists in interventional radiology. Patients were under local
anaesthesia with conscious sedation. Tumour localization and
ablation were guided by trans-abdominal ultrasound or CT scan,
or by both modalities. If the nature of the lesion was not diagnos-
tic by radiological or biochemical means, a tumour biopsy was
performed immediately prior to the ablation through a co-access
needle system. Only malignant lesions were included in the
present study. A RF 3000 Radiofrequency Generator with LeVeen
needles (Boston Scientific, Natick, MA, USA) was used in almost
all percutaneous cases, with the aim of covering a 0.5–1.0 cm
margin around the lesion. Using the standard algorithm, the
power was increased step by step until either the required appli-
cation time had elapsed or the power declined.15 Tumours were
treated with multiple overlapping ablations when needed. At the
end of procedure, the needle track was burned.
All surgical RFA procedures were performed by the same team
of HPB surgeons. The technique was the same as the one previ-
ously described.13 Laparoscopic RFAs were performed with a 30°
laparoscope with CO2 pneumoperitoneum. After a full laparo-
scopic examination to exclude the presence of peritoneal second-
ary, the intra-hepatic tumours were localized by intra-operative
laparoscopic ultrasound (linear array, Aloka SSD-2000; Aloka Co.
Ltd., Tokyo, Japan). A Radionics Cool-tip RF System (Tyco
Healthcare, Burlington, MA, USA) was used. The RF current was
emitted for 12 min per insertion of the electrode. At the end of
ablation, the current and cooling circuit was switched off, with the
electrode remaining in place for 30 s to display the post-ablation
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temperature, which was aimed at above 60°C. Multiple overlap-
ping ablations were performed when necessary to ensure complete
ablation, as in the percutaneous group. The needle track was then
burned at the end of the procedure.
Open RFA procedures were performed via a right subcostal
incision. After adequate mobilization, tumour localization and
electrode placement were guided by intra-operative ultrasound
(T-probe, Aloka SSD-2000). Both the Radionics Cool-tip RF
System (Tyco Healthcare) and RF 3000 Radiofrequency Generator
(Boston Scientific) systems were used, whichever was more appli-
cable. In general, LeVeen needles (Boston Scientific) were avoided
in lesions located peripherally. No Pringle clamping was applied in
any of the patients.
Patients’ follow-up
Patients were assessed at our out-patient clinic by the same team
of HPB surgeons. The median follow-up period was 29.0 months
(range, 2.0–101.4). A full clinical assessment and all complications
were documented. Complications were categorized according to
the Clavien–Dindo classification.16 Grade I and grade II were
defined as minor complications, whereas grade III (requiring sur-
gical, endoscopic or radiological intervention) or above were con-
sidered as major complications. Patients were assessed by contrast
enhanced CT scans at 1, 3, 6 months and then yearly after RFA
treatment. The ablation response was defined as ‘incomplete’ if
there was existence of arterial enhanced areas on the 1-month
post-ablation imaging. For the completely-ablated lesions, the
presence of an enhanced appearance on subsequent scans would
be defined as ‘recurrence’. Intra-hepatic recurrences were further
divided into an ‘ablated site’ or at a ‘distant site’. Extra-hepatic
recurrences were determined by CT scans, chest X-rays, bone
scans, positron emission tomography scans or tissue histology
according to clinical need. Patients with a tumour recurrence were
treated accordingly, with an individual’s best interest. They were
also managed by oncologists as part of the multi-disciplinary
team.
Statistical analysis
Parameters including tumour number and size, length of hospital
stay, procedure-related complications and treatment outcome
were analysed and compared between the percutaneous and sur-
gical groups. Continuous data were expressed as median (range)
and tested using the Mann–Whitney U-test. Categorical data were
compared using the c2 test or Fisher’s exact test. Survival data were
calculated using the Kaplan–Meier method and were compared by
the log-rank test. The level of significance was set at 0.05 for all
tests.
Results
From May 2003 to September 2011, 233 patients (177 men and 56
women) undergoing RFA for malignant liver tumours were evalu-
ated. The nature of malignancy included HCC (176 patients,
75.5%) and liver metastases (57 patients, 24.5%), with a total of
293 tumours ablated. Percutaneous ablation was performed in 136
patients (58.4%); laparoscopic ablation in 22 patients (9.4%); and
open ablation in 75 patients (32.2%). Patient demographics and
tumour characteristics are listed in Table 1. Concomitant proce-
dures performed in the surgical group are listed in Table 2.
Complications
All RFA complications are listed in Table 3. There was no
treatment-related 30-day mortality documented in any of the
Table 1 Patient demographics and tumour characteristics
Percutaneous Surgical P-value
Number of patients 136 97
Gender (Male/Female) 98:38 79:18 0.098
Median age (years) 61 (35–93) 59 (38–83) 0.045*
Number of tumours 145 148
Diagnosis
HCC 100 (73.5%) 76 (78.4%) 0.399
Liver metastases 36 (26.5%) 21 (21.6%)
No. of tumours
ablated per
patient
Solitary 127 (93.4%) 73 (75.3%) <0.001*
Multiple 9 (6.6%) 24 (24.7%)
Median tumour
size (cm)
2.0 (0.7–5.0) 2.2 (0.5–8.0) 0.725
Median hospital
stay (days)
2 (1–9) 6 (2–27) <0.001*
Median follow-up
period (months)
31.0 (2.2–75.1) 27.7 (2.0–101.4) 0.992
*P-value < 0.05, Mann–Whitney U-test.
HCC, hepatocellular carcinoma.
Table 2 Concomitant surgical procedures during radiofrequency
ablation (RFA)
Laparoscopic
(%)
Open
(%)
Cholecystectomy only 4 (18.2) 31 (41.3)
Hepatectomy only – 7 (9.3)
Colectomy only 1 (4.5) 2 (2.7)
Hepatectomy and cholecystectomy – 5 (6.7)
Hepatectomy and excision of
peritoneal nodules
– 1 (1.3)
Hepatectomy and small bowel
resection
– 1 (1.3)
Cholecystectomy and resection of liver
haemangioma
– 1 (1.3)
Cholecystectomy and colectomy – 1 (1.3)
Right adrenalectomy – 1 (1.3)
Hernia repair (inguinal and
paraumbilical)
– 1 (1.3)
Coeliac lymph node dissection – 1 (1.3)
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patients. Overall, the major complication rate was 4.7% (11/233)
and the minor complication rate was 9.0% (21/233).
Treatment outcome
The treatment outcome is summarized in Table 4. A complete
ablation was achieved in 83.7% (195/233 patients). The common
sites of extrahepatic recurrence are listed in Table 5. The cumula-
tive overall survival of all patients after RFA is shown in Fig. 1. The
survival rates of patients with HCC and liver metastases after RFA
were observed separately (Table 6). Percutaneous and surgical
RFA offered no significant difference in survival for patients with
HCC (P-value = 0.512) or liver metastases (P-value = 0.443).
Patients with liver metastases had a worse prognosis than those
with HCC after 1 year of RFA treatment.
Discussion
HCC and colorectal liver metastasis are the two most common
malignant liver tumours.9 Chronic HBV infection is a predomi-
nant factor predisposing patients to HCC in Southeast Asia, Africa
and Japan.3 In the western world, an increasing trend in the inci-
dence has been observed recently, particularly in the United States,
Table 3 Complications of radiofrequency ablation (RFA)
Percutaneous Surgical P-value
Immediate Subcapsular
haematoma (n = 1)
Pleural effusion
(n = 1)
Misplacement of a
catheter into the
small bowel
during artificial
ascites (n = 1)
Right adrenal
haemorrhage (n = 1)
Superficial skin burn
(n = 1)
Gastric serosal burn
(n = 1)
NS
Early Atrial fibrillation
(n = 1)
Esophageal varices
(n = 1)
Pleural effusion (n = 4)
Wound infection
(n = 4)
Chest infection (n = 3)
Atrial fibrillation (n = 3)
Ascites (n = 2)
Subhepatic collection
(n = 2)
DVT (n = 1)
Liver abscess (n = 1)
Lung collapse (n = 1)
Supra-ventricular
tachycardia (n = 1)
Wound bleeding
(n = 1)
<0.001*
Delay - Needle track
seeding (n = 1)
Nil NS
*P-value < 0.05, Fisher's exact test.
NS, non-significant.
Table 4 Radiofrequency ablation (RFA) treatment outcome
Percutaneous Surgical P-value
Complete ablation (%) 84.6 82.5 0.617
HCC 87.0 80.3 0.226
Liver metastases 77.8 90.5 0.295
Intra-hepatic recurrence (%) 72.0 65.9 0.320
At RFA site 29.4 24.7 0.431
At distant site 42.6 41.2 0.830
Extra-hepatic recurrence (%) 19.9 25.8 0.285
Overall survival (%)
1 year 93.9 88.9
2 years 74.5 67.6
3 years 61.1 59.5
5 years 40.3 47.4
HCC, hepatocellular carcinoma.
Table 5 Sites of extrahepatic recurrence in the 52 patients
Sites Number of patients (%)
Lung 26 (50.0)
Bone 14 (26.9)
Lymph nodes 7 (13.5)
Peritoneum 6 (11.5)
Adrenal 4 (7.7)
Brain 2 (3.8)
Mesocolon 2 (3.8)
Omentum 2 (3.8)
Skin 2 (3.8)
Kidney 1 (1.9)
Pancreas 1 (1.9)
Small bowel mesentery 1 (1.9)
Spleen 1 (1.9)
P-value=0.853
Log-rank test
Percutaneous approach
Surgical approach
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Figure 1 Cumulative overall survival of all patients after radiofre-
quency ablation (RFA)
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Canada and southern Europe, of which HCV infection is the
major contributing factor.3–5 While a hepatectomy remains the
‘gold standard’ for treating malignant liver tumours, only a small
proportion of patients are suitable candidates for a curative-intent
resection.7 This may be as a result of patients’ comorbidities, poor
liver reserve or an unfavorable anatomical tumour location. One
of the best alternatives for these patients who cannot undergo a
curative hepatectomy is RFA. This technique has developed
rapidly over recent years and promises better local control com-
pared with other local ablative therapies, such as percutaneous
ethanol injection.17,18 Consensus meetings of major scientific soci-
eties have presented guidelines for the use of RFA.11,12 The Barce-
lona clinic liver cancer staging and treatment assessment system is
widely used worldwide.19 Patients with early stage disease can be
effectively treated by resection, transplantation or percutaneous
ablation with the possibility for a long-term cure and 5-year sur-
vival ranging from 50% to 70%.12,20
Certain RFA-related morbidities are recognized and have been
widely published.21,22 The present study reported no procedure-
related mortality; and a major and minor complication rate of
4.7% and 9.0%, respectively. The complication profile was very
similar to other previous studies.22,23 There were publications that
focused on methods to minimize related complications.24,25 Sig-
nificant risk factors associated with treatment morbidity included
hyperbilirubinaemia (>20 umol/l), multiple tumour nodules, sur-
gical approach and early experience (<50 patients).26
A potential complication encountered lately in the percutane-
ous group was needle track seeding. This condition was diagnosed
in one patient 9 months after RFA for her colorectal liver second-
ary. She died subsequently of carcinomatosis. Bonatti et al.
reported a case of skin implant metastasis after percutaneous RFA
for colorectal liver secondary.27 This has also been described after
percutaneous RFA for HCC performed with single cool-tip elec-
trode.28 Intrahepatically, this condition could be avoided if the
normal liver parenchyma was traversed, and the track adequately
coagulated during removal of electrode at the end of procedure.
In the surgical group, significantly more complications were
encountered, mainly from respiratory events (pleural effusion,
chest infection and lung collapse) and wound infections. This
might be explained by the concomitant operations performed and
more tumours being ablated per patient in the surgical arm. These
could also be the reasons for the significantly longer hospital stay
for the surgical group. A similar prospective non-randomized
study comparing the morbidity and mortality of laparoscopic
versus open RFA for hepatic malignancies was published by a
Belgium group.29 The author demonstrated that the minimally
invasive group was associated with significantly less blood loss, a
shorter duration of surgery, fewer post-operative complications
and shorter hospital stay.
The therapeutic efficacy of RFA for liver tumours has been
examined. Six clinical cohort studies on HCC have been reported
since 2005 (Table 7).30–35 The present study on 233 patients with a
median follow-up of 29 months, demonstrated 0% mortality and
a 4.7% major complication rate. The 1-, 3- and 5-year overall
survival rates were all comparable to the above international
figures.
The non-randomized nature of this study was one of its major
limitations. A randomized controlled trial may not be applicable
in comparing the percutaneous versus the surgical approach, as
some patients will definitely benefit from the former if they are
not candidates for general anaesthesia. Some tumours, because of
their location, would definitely be ablated using the surgical
approach if percutaneously not feasible. There were data support-
ing better local control after a surgical approach,26,36 whereas other
reports found no statistically significant difference.37,38 In a meta-
analysis by Mulier et al., the surgical approach yielded superior
local control than a percutaneous approach, independent of the
size of the tumours.39 In fact, the authors concluded that the
short-term benefits of less invasiveness for the percutaneous route
could not outweigh the longer-term higher risk of local recur-
rence, and the percutaneous route should mainly be reserved for
patients who could not tolerate a laparoscopy or laparotomy.
There were several factors that possibly affected the outcomes
in different approaches. In fact, the two groups under comparison
were not identical. In the surgical approach, the intra-operative
ultrasound probe is placed directly on the liver surface, without
sound attenuation by skin and subcutaneous tissue, as compared
with external ultrasound used in the percutaneous group. Previ-
ous studies have demonstrated an increase in the tumour detec-
tion rate by surgical ultrasound. It was claimed that detection of
small satellite nodules and identification of tumour margins could
be more precise36,38,40
Tumours located at the superior aspect of the right lobe of the
liver would need full mobilization of the liver before electrode
insertion. This has to be done through a surgical approach. Fur-
thermore, the surgical route could allow multiple parallel reinser-
tions of a needle when overlapping coagulations are needed. In the
percutaneous route, the access of the tumour and degree of
freedom for insertion of a needle could be jeopardized at certain
Table 6 Survival after hepatocellular carcinoma (HCC) and liver
metastases by percutaneous and surgical approach
Percutaneous Surgical
HCC survival (%) (n = 100) (n = 76)
1 year 92.8 87.3
2 years 82.1 69.3
3 years 68.7 61.0
5 years 47.2 48.6
Liver metastases survival
(%)
(n = 36) (n = 21)
1 year 97.1 94.7
2 years 54.8 61.3
3 years 41.9 54.5
5 years 23.0 38.6
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locations, and usually, overlapping ablations are performed
through the same track upon withdrawal of the needle.
The Pringle manoeuver can only be applied to the surgical
group. Although this manoeuver has not been used in the present
study, it has been shown that it can prevent dissipation of heat
from a vascular tumour and thus improve the likelihood of com-
plete ablation.41 Laparoscopy by itself, with a 12 mmHg pneu-
moperitoneum, alters the haemodynamics causing a 40% decrease
of portal vein flow even without a Pringle, with a subsequent
increase in the coagulation size.42
The preliminary results of RFA on liver malignancies was
reported 3 years ago,13 which showed no difference in short-term
outcome using the percutaneous or surgical approach. The two
major shortages of that study were the limited number of patients
and the relatively short follow-up time. The present study was an
extension of the previous one, of which the intention was to
address the longer-term oncological outcome with a larger
number of patients. The results reported in the two studies were
consistent.
In conclusion, the present study with an extended period of
follow-up, demonstrated that RFA is an effective modality of
treatment for HCC and liver metastases. No difference can be
demonstrated between the percutaneous and surgical approach
used, in terms of tumour recurrence and survival rates. Concomi-
tant operative procedures can be performed with the surgical
approach, which was associated with significantly more wound
and respiratory complications and longer hospital length of stay.
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